Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
Revenue (Most Recent Fiscal Year) | $2.35B |
Net Income (Most Recent Fiscal Year) | $1.13B |
PE Ratio (Current Year Earnings Estimate) | 6.95 |
PE Ratio (Trailing 12 Months) | 6.26 |
PEG Ratio (Long Term Growth Estimate) | 0.78 |
Price to Sales Ratio (Trailing 12 Months) | 6.97 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.63 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.01 |
Pre-Tax Margin (Trailing 12 Months) | 72.20% |
Net Margin (Trailing 12 Months) | 48.22% |
Return on Equity (Trailing 12 Months) | 26.93% |
Return on Assets (Trailing 12 Months) | 15.93% |
Current Ratio (Most Recent Fiscal Quarter) | 7.90 |
Quick Ratio (Most Recent Fiscal Quarter) | 7.90 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.61 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $16.88 |
Earnings per Share (Most Recent Fiscal Quarter) | $1.15 |
Earnings per Share (Most Recent Fiscal Year) | $4.49 |
Diluted Earnings per Share (Trailing 12 Months) | $1.89 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 597.43M |
Free Float | 485.60M |
Market Capitalization | $16.41B |
Average Volume (Last 20 Days) | 2.29M |
Beta (Past 60 Months) | 0.45 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 18.72% |
Percentage Held By Institutions (Latest 13F Reports) | 54.35% |
Annual Dividend (Based on Last Quarter) | $0.84 |
Dividend Yield (Based on Last Quarter) | 3.06% |